Bring On The Competition In Obesity Drugs: Novo Nordisk CEO Optimistic About Prolonged Patient Adherence to Obesity Drug Wegovy
Lars Fruergaard Jorgensen, CEO of Novo Nordisk A/S (NYSE: NVO), shared insights during the JPMorgan Healthcare conference, highlighting Wegovy's efficacy for weight loss, indicating that patients are likely to continue with Wegovy for more extended periods compared to
